InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,346.56
(
-1.84%
)
US TECH 100
17,900.00
(
-2.65%
)
Dow Jones
39,737.26
(
-1.51%
)
Brent Oil
77.36
(
0.00%
)
Bitcoin
59,959.49
(
-2.38%
)
Post# of 252778
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 65606

Wednesday, 08/27/2008 9:22:59 AM

Wednesday, August 27, 2008 9:22:59 AM

Post# of 252778
>Apixaban did manage to show a statsig lower rate of clinically relevant bleeding (a safety rather than efficacy endpoint) relative to Lovenox, which bodes well for other Apixaban trials in VTE

These safety vs. efficacy results, makes me wonder if Apixaban's dose wasn't too low.


Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up